布美他尼
医学
耐受性
水肿
利尿剂
鼻腔给药
肾脏疾病
药理学
肾
利尿剂
肝病
鼻喷雾剂
慢性肝病
药代动力学
麻醉
临床试验
药效学
背景(考古学)
内科学
胃肠病学
鼻粘膜
叙述性评论
心力衰竭
临床药理学
作者
Mario Enrico Canonico,Domenico Simone Castiello,Christian Basile,Luca Bardi,Marisa Avvedimento,Costantino Mancusi,Giuseppe Gargiulo,Giuseppe Giugliano,Raffaele Piccolo,Anna Franzone,Carmine Morisco,Eugenio Stabile,Giovanni Esposito
标识
DOI:10.1080/20415990.2026.2755249
摘要
Edema is a common manifestation of heart failure, advanced liver disease, and chronic kidney disease, reflecting an imbalance between sodium and water homeostasis that frequently requires treatment with loop diuretics. Despite their efficacy, oral formulations may be affected by variable gastrointestinal absorption, and delayed onset of action, whereas intravenous formulations require healthcare-based delivery. These challenges have stimulated interest in alternative drug delivery strategies able to provide a rapid, and predictable diuretic therapy. Intranasal bumetanide has emerged as a novel formulation designed to overcome these limitations by enabling systemic absorption through the highly vascularized nasal mucosa while bypassing the gastrointestinal tract. Early pharmacokinetic and pharmacodynamic studies in healthy volunteers show that intranasal bumetanide achieves rapid and consistent systemic exposure, with diuretic and natriuretic effects comparable to conventional diuretic formulations and acceptable short-term tolerability. However, direct clinical efficacy of intranasal bumetanide in patients with edema has not yet been prospectively established, and several questions regarding its optimal clinical management, long-term effectiveness, and cost-effectiveness are yet to be addressed. This narrative review aims to discuss the pharmacological characteristics, clinical efficacy, safety, and tolerability of bumetanide nasal spray, with emphasis on its use in patients with edema secondary to cardiac, hepatic, and renal disorders.
科研通智能强力驱动
Strongly Powered by AbleSci AI